Multimodal Retinal Imaging of Cerebrovascular Stroke (OCTAV)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03964610|
Recruitment Status : Recruiting
First Posted : May 28, 2019
Last Update Posted : February 25, 2020
The hypothesis is that in patients with stroke, abnormalities of retinal microvascularization shown on color fundus photography and the depletion of retinal capillary density evaluated by OCT-A are markers of acute impairment of microcirculation of the central nervous system and are correlated with lesions on brain imaging.
Patients hospitalized for stroke MRI-confirmed, will be included. An ophthalmologic assessment including color fundus photography (CFP) and OCT-A will be carried out after stabilization and at 3 months follow-up. Outcomes assessor will be blinded.
|Condition or disease||Intervention/treatment|
|Stroke Cerebrovascular Accidents||Diagnostic Test: color fundus photography (CFP) and OCT-A|
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||Multimodal Retinal Imaging of Cerebrovascular Stroke|
|Actual Study Start Date :||November 15, 2019|
|Estimated Primary Completion Date :||November 15, 2020|
|Estimated Study Completion Date :||February 15, 2021|
- Diagnostic Test: color fundus photography (CFP) and OCT-A
Included patients will have an ophthalmologic assessment (OCT-A and CPF) after stabilization and at 3 months follow-up.
- Presence of an anomaly in color fundus photography or an anomaly of retinal capillary density to OCT-A [ Time Frame: 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03964610
|Contact: Rabih Hageemail@example.com|
|Contact: Amélie Yavchitzfirstname.lastname@example.org|